Search
News & Events
Replication of rare aggressive brain cancer could pave the way for better treatmentsIn an Australian-first, The Kids Research Institute Australia researchers have developed a new tool that could improve outcomes for children with a highly aggressive type of brain cancer.
News & Events
'Natural killers' potential new cancer weaponThe Cancer Immunology team at The Kids is investigating how the body's 'natural killer' cells can be harnessed to fight cancer – whilst also protecting kids from nasty chemotherapy side effects.
News & Events
Experts Pledge Global Assault on Kids’ CancerA global plan to tackle one of the most aggressive types of childhood brain tumours will be developed as a result of a meeting of international experts in WA.
News & Events
NHMRC funding boost to child health researchThe Kids researchers will use nearly $8.5 million awarded by the National Health and Medical Research Council (NHMRC) to tackle health issues including respiratory disease, brain cancer, vaccination and Aboriginal health.
News & Events
Lab results confirm promise of new immunotherapy gel for kids cancerNewly published research from The Kids Research Institute Australia and The University of Western Australia has found a gel applied during surgery to treat sarcoma tumours is both safe and highly effective at preventing the cancer from growing back.
News & Events
Researchers narrow down field of new treatments for most common childhood brain cancerCancer researchers have narrowed-down the field of immunotherapy drugs which could be used to tackle a form of childhood brain cancer.
Research
The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness programTranscriptional cofactors of the ETO family are recurrent fusion partners in acute leukemia. We characterized the ETO2 regulome by integrating transcriptomic and chromatin binding analyses in human erythroleukemia xenografts and controlled ETO2 depletion models. We demonstrate that beyond its well-established repressive activity, ETO2 directly activates transcription of MYB, among other genes.
Research
Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective mannerChemotherapy is included in treatment regimens for many solid cancers, but when administered as a single agent it is rarely curative. The addition of immune checkpoint therapy to standard chemotherapy regimens has improved response rates and increased survival in some cancers. However, most patients do not respond to treatment and immune checkpoint therapy can cause severe side effects. Therefore, there is a need for alternative immunomodulatory drugs that enhance chemotherapy.
Research
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialBRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma.
Research
Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia PatientsB-cell acute lymphoblastic leukaemia (B-ALL) is characterised by diverse genomic alterations, the most frequent being gene fusions detected via transcriptomic analysis (mRNA-seq). Due to its hypervariable nature, gene fusions involving the Immunoglobulin Heavy Chain (IGH) locus can be difficult to detect with standard gene fusion calling algorithms and significant computational resources and analysis times are required. We aimed to optimize a gene fusion calling workflow to achieve best-case sensitivity for IGH gene fusion detection.